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The H Syndrome Is Caused by Mutations
in the Nucleoside Transporter hENT3
Vered Molho-Pessach,1,4 Israela Lerer,2 Dvorah Abeliovich,2 Ziad Agha,1 Abdulasalam Abu Libdeh,5
Valentina Broshtilova,6 Orly Elpeleg,3 and Abraham Zlotogorski1,4,*
The H syndrome is a recently reported autosomal-recessive disorder characterized by cutaneous hyperpigmentation, hypertrichosis, hep-
atosplenomegaly, heart anomalies, hearing loss, hypogonadism, short stature, hallux valgus, and ﬁxed ﬂexion contractures of the toe
joints and the proximal interphalangeal joints. Homozygosity mapping in ﬁve consanguineous families resulted in the identiﬁcation
of mutations in the SLC29A3 gene, which encodes the equilibrative nucleoside transporter hENT3. Three mutations were found in 11
families of Arab and Bulgarian origin. The ﬁnding of several differentmutations in a small geographic region implies that theH syndrome
might be rather common. The identiﬁcation of mutations in the SLC29A3 gene in patients with a mild clinical phenotype suggests that
this is a largely underdiagnosed condition and strongly suggests that even oligosymptomatic individuals might have the disorder.The H syndrome is a recently described autosomal-reces-
sive genodermatosis with systemic manifestations. The
term H syndrome refers to the major clinical and labora-
tory ﬁndings of hyperpigmentation and hypertrichosis,
hepatosplenomegaly, heart anomalies, hearing loss, hypo-
gonadism, low height, and occasionally, hyperglycemia.1
We recently reported on ten Arab patients (nine males
and one female) originating from six consanguineous fam-
ilies from a small region near Jerusalem. These patients
suffered from hyperpigmented, hypertrichotic, and indu-
rated cutaneous patches involving the middle and lower
parts of the body. The onset of the cutaneous lesions was
at the ﬁrst or second decade of life. Additional systemic
features were sensorineural hearing loss, cardiac anoma-
lies, hepatosplenomegaly, scrotal masses, endocrinopathy
(short stature, gynecomastia), exophthalmos with normal
thyroid function, angiopathy (varicosities, dilated lateral
scleral vessels, and facial telangiectases), and camptodac-
tyly. Laboratory evaluation revealed growth-hormone
deﬁciency and hypergonadotrophic hypogonadism with
azoospermia. Histopathological examination of involved
skin showed hyperpigmentation of the basal layer with
seborrheic keratosis-like acanthosis, inﬁltration of CD68-
positive histiocytes, and a perivascular mononuclear inﬁl-
trate with plasma cells and mast cells throughout the
dermis and subcutaneous fat.1 The syndrome may not be
limited to our region because seven other patients, six
males and one female with a similar phenotype, have
already been reported from other parts of the world.2–4
The subjects of the present study were the ten previously
reported patients and an additional nine patients: three
males and four females from three families (G–I), originat-
ing from the same geographic area, and onemale (Family J)
from 50 Km away and a previously reported Bulgarian
patient (Family K)3 (Figure 1).The clinical ﬁndings of patients from families G-J (Fig-
ure 1 and Table 1) were similar to those of the previously
reported patients.1 Additional clinical features were prom-
inent: Hallux valgus with ﬁxed ﬂexion contractures of the
toe joints (8/10 patients) and ﬁxed ﬂexion contractures of
the hands’ proximal interphalangeal joints (7/9) appeared
during the ﬁrst decade of life. More prominent changes
occurred in female patients, and some patients displayed
lateral tibial torsion (4/9) and myeloﬁbrosis (1/9). Review-
ing the clinical ﬁndings1 we now ﬁnd it likely that the pre-
viously reported camptodactyly is in fact a milder form of
the contractures of the proximal interphalangeal joints.
Another exceptional ﬁnding was noted in the female pa-
tient III-7, whose indurated and hyperpigmented patches
not only were present at the middle and lower half of the
body but also extended to the trunk and neck with a retic-
ular and annular morphology. This patient had hard
subcutaneous masses with overlying hyperpigmentation
in the mons pubis, a ﬁnding that has previously been
reported only in males. Interestingly, two other female
patients; GII-10 and HII-2, lacked the classical cutaneous
ﬁndings of hyperpigmentation, hypertrichosis, and indu-
ration of the lower limbs. At the time of writing, all the pa-
tients were alive, except for patient IIII-5, who died at nine
years of age, probably because of patent ductus arteriosus
with pulmonary hypertension and recurrent pneumonia.
This patient had also suffered from hearing loss, short
stature, and hepatomegaly. The oldest surviving patient
(HII-2) was a 50-year-old female with short stature, marked
skeletal changes of the hands and feet, and hypogonadism
manifesting as delayed puberty and primary amenorrhea.
Another unique feature in this patient was red cell aplasia
that developed at the age of 29 and necessitated multiple
blood transfusions and splenectomy and was attributed
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Figure 1. Pedigrees and Clinical Findings of Four Novel Families with H Syndrome and of a Previously Reported Bulgarian Family
Affected individuals are marked by gray symbols.
Pedigrees for families G–K are shown at left.
(A) Hyperpigmentation of inner thighs in patient GII-3.
(B) More diffuse and extensive hyperpigmentation in patient KII-1.
(C) Fixed flexion contractures of proximal interphalangeal joints in patient HII-2.
(D) Hallux valgus and fixed flexion contractures of toe joints in patient III-6.previously reported families B and D1 identiﬁed two more
affected patients (BII-6 and DII-7). At the age of 18 and
22 years, the only abnormalities in these patients were
dilated lateral scleral vasculature and prominent gyneco-
mastia.
Blood samples were collected from 17 patients and 22
healthy family members of the ten families after consent
was obtained from the Institutional Review Board and
the patients. GeneChip Human Mapping 50K and 250K
SNP Array of Affymetrix was used for performing a ge-
nome-wide analysis of single-nucleotide polymorphisms
with the DNA samples of patients AII-8, CII-2, CII-4,
DII-2, EII-1, and FII-6. A single region of homozygosity
shared by ﬁve patients from four families (C, D, E, and F)
was identiﬁed in chromosome 10q21.3–q22.1 (haplotype
cluster rs7894724–rs7081747). This region was not shared
by patient AII-8. We next genotyped all members of the six530 The American Journal of Human Genetics 83, 529–534, Octobefamilies for polymorphic microsatellites (D10S1665,
D10S529, D10S537, D10S1650, and D10S606) spanning
the homozygous region on chromosome 10. The analysis
revealed two distinct allele patterns segregating with the
disorder. One of these was in family B, and the other was
in families C–F, for whom a key recombination event oc-
curred between markers D10S529 and D10S537 in family
C but not in families D, E, and F (Figure 2). Patient AII-8
was a compound heterozygote of both haplotypes and
had a recombination event between markers D10S1665
and D10S529. The recombination event in family C
enabled us to narrow the interval of linkage to a 1.53 Mb
region, ﬂanked by markers D10S529 and D10S606
(71,509,225–73,039,899). This region contained 21 known
genes, and we were able to exclude 14 of them by direct
sequencing: AIFM2 [gene ID 84883], ADAMTS14 [MIM
607506], EIF4EBP2 [MIM 602224], C10ORF54 [gene IDr 10, 2008
Table 1. Clinical Features of Patients in Families G–J
Patient GII-3 GII-10 HII-2 III-6 III-7 IIII-5 IIII-6 JII-1
Age at examination
(years)
13 20 50 20 17 Died at
age 9
13 12
Sex male female female female female male male male
Height(m)/Weight
(kg)
1.32/36 1.63/53 1.46/46 1.65/62 1.60/55 known short
stature
1.37/34 1.10/23
Cutaneous
hyperpigmentation,
hypertrichosis and
induration
genitals,
inner
thighs,
shins
  inner and
posterior
thighs,
shins
inner thighs,
shins,
hyperpigmented
reticulate
patches over
trunk
NA lower back
and abdomen,
genitals,
thighs, shins,
dorsum of foot
mid-abdomen
and back,
genitals, thighs,
shins, dorsum
of foot, forearms
Genital examination subcutaneous
masses,
micropenis
   subcutaneous
masses
NA subcutaneous
masses,
micropenis
subcutaneous
masses,
micropenis
lack of
secondary
sexual signs
Hepatosplenomegaly hepatomegaly  hepatomegaly   hepatomegaly þ þ
Heart examination mild pulmonic
stenosis
2/6 systolic
murmura
 mild
pericardial
effusion
 patent ductus
arteriosus with
right to left
shunt, left
superior vena
cava to
coronary sinus
pulmonary
hypertension
2/6 systolic
murmura
Hearing loss þ þ  þ þ þ  þ
Hallux valgus þ þ þ þ þ þ þ 
severe rocker
bottom
deformity
of foot
Fixed flexion
contracture of
proximal
interphalangeal
joints
þ mild þ þ þ þ NA þ þ
Lateral tibial
torsion
  þ þ þ   þ
Varicose veins þ þ þ þ þ NA  
stasis ulcers
Exophthalmos   þ þ  NA  
Dilated lateral
scleral vasculature
þ þ  þ þ NA þ þ
Facial telangiectases  þ þ þ þ þ þ 
Mental retardation       mild 
Other findings arcus senilis
hematologic
illness
arcus senilis arcus senilis,
gynecomastia
NA, not available for examination.
a Echocardiography was unavailable.64115], PPA1 [MIM 179030], H2AFY2 [gene ID 55506],
LRRC20 [gene ID 55222], NODAL [MIM 601265], PRF1
[MIM 170280], TYSND1 [MIM 611017], SAR1A [MIM
607691], PSAP [MIM 176801], NPFFR1 [gene ID 64106],
and C10ORF27 [gene ID 219793]. Sequencing of the six
exons of the SLC29A3 gene [gene ID 55315] with intronic
primers (Table S1 in the Supplemental Data available on-
line) revealed homozygosity for two missense mutations
in exon 6: a c.1279G > A mutation, changing glycine
427 to serine (G427S) in all patients of families B and I,
and a c.1309G > A mutation, changing glycine 437 to
arginine (G437R) in all patients of families C–H. TheThe Amerionly patient in family A, AII-8, was a compound heterozy-
gote for bothmutations (Figure 3 and Table 2). This patient
resides in a village located between families B and C, which
have the c.1279G > A and c.1309G > A mutations, respec-
tively. Sequence analysis of exon 6 in the DNA sample of
patient JII-1 revealed homozygosity for a single-nucleotide
deletion, c.1045delC, which is predicted to result in
a frameshift and the generation of a stop codon at residue
404 of the protein (Figure 3). Restriction digestion analysis
with PvuII was used for detecting the G427Smutation after
the introduction of a mismatch four bases upstream the
mutation in the reverse primer. The Eco1471 (StuI)can Journal of Human Genetics 83, 529–534, October 10, 2008 531
Figure 2. Haplotype Analysis Performed in Six Families with H Syndrome
Affected individuals are marked by gray symbols. The disease-associated haplotypes in the linked interval on chromosome 10q21.3–q22.1
are shown by vertical bars (red and green) in families A–F. Alleles excluded by recombination events are marked in pink. The physical
locations of the polymorphic microsatellites are given near the haplotype for individual AI-2.restriction enzymewas used for detecting the G437Rmuta-
tion. All mutations segregated with the disease within the
families, and no other mutations were identiﬁed in the
other ﬁve exons of the SLC29A3 gene.
Subsequently, we analyzed the six exons of the SLC29A3
gene in a previously reported Bulgarian patient with a sim-
ilar phenotype. The patient originated from a nonconsan-
guineous family, and his parents came from the same small
town. He suffered from growth retardation, hepatomegaly,
gynecomastia, hypogonadism, diabetes mellitus, malab-
sorption, and skin changes consisting of induration,
hyperpigmentation, and hypertrichosis on the anterior
aspect of both thighs, lower abdomen, and scrotum.3 Re-
examination of the patient at 23 years revealed additional
H-syndrome-characteristic features, including facial telan-
giectases, mild proptosis, and bilateral camptodactyly.
Sequence analysis revealed homozygosity for the G427S
mutation due to the same nucleotide change as in the532 The American Journal of Human Genetics 83, 529–534, Octobeindex families A, B, and I. However, the microsatellite hap-
lotype was completely different (Table S2), indicating that
the Bulgarian mutation arose independently.
362 and 212 control chromosomes of individuals of the
same geographical and ethnic background as families A–I
were examined for the presence of the c.1279G > A and
c.1309G > Amutations, respectively. Four and two hetero-
zygous individuals, respectively, were identiﬁed, indicating
a 1% frequency of both diseased alleles in this population.
None of the mutations was found in 60 chromosomes
derived from individuals of Jewish origin or in 76 control
chromosomes of individuals of European or Bulgarian
origin.
The SLC29A3 gene encodes the human equilibrative
nucleoside transporter 3 (hENT3), a member of the equili-
brative nucleoside transporter (ENT) family that mediates
passive sodium-independent transport of nucleosides.
Members of this family possess 11 transmembrane helices,r 10, 2008
Figure 3. Mutations c.1279G > A, c.1309G > A, and c.1045delC in the SLC29A3 Gene
(A) Conservation among species of amino acid positions affected by G427S and G437R missense mutations. The mutated amino acids are
marked by blue and red, respectively.
(B) The single base-pair substitution mutations are shown (vertical arrow) in DNA samples of patients CII-2 (c.1309G > A), BII-3
(c.1279G > A), and AII-8 (c.1309G > A; c.1279G > A). The wild-type is shown in the upper panel.
(C) The c.1045delC mutation in patient JII-1 is shown in the lower panel, and the wild-type is shown in the upper panel.with a cytoplasmic N terminus and an extracellular C
terminus.5 hENT3 is a 475 amino acid protein, and both
Gly427 and Gly437 residues are part of the tenth trans-
membrane domain (TMD), which is highly conserved
from C. elegans to humans. Mutations in this TMD are
therefore likely to perturb the transporter function. Simi-
larly, the single-nucleotide deletion located at the eighth
TMD is expected to result in a truncated protein lacking
the tenth and 11th TMDs and to disrupt the eighth and
ninth TMDs. Nucleoside transporters are essential for nu-
cleotide synthesis by salvage pathways in cells that lack
de novo pathways and are the route of cellular uptake for
cytotoxic nucleosides used in cancer and viral chemother-
apy.6 Two families of nucleoside transporters are known in
mammals: the concentrative nucleoside transporter
(SLC28) family, which consists of active, sodium-depen-
Table 2. Mutations in SLC29A3 in 11 Families with
Autosomal-Recessive H Syndrome
Family Mutation
A G427S; G437R
B, I, K G427S
C–H G437R
J c.1045delCThe Americdent transporters found mainly in specialized epithelial
tissues7,8, and the ENT family. Of the four members of
the ENT family, ENT1, 2, and 4 are primarily located at
the cell surface, although ENT1 has also been found in liver
mitochondria.9 hENT3 is widely expressed in adult and
fetal human tissues; the highest levels are detected in
placenta, uterus, ovary, spleen, lymph node, and bone
marrow. Transport experiments with hENT3 expressed in
Xenopus oocytes revealed that this transporter has a broad
selectivity for nucleosides. hENT3 cellular sublocalization
is still in doubt: the protein was found to colocalize with
lysosomal markers in cultured human cells and was sug-
gested to be a late endosomal/lysosomal transporter
involved in the export of nucleosides from the lysosomal
interior.10 A recent abstract suggested the localization of
this transporter to the mitochondria in multiple cell
types.11 Gene silencing of hENT3 in a placental cell line
signiﬁcantly decreased both cellular andmitochondrial up-
take of nucleosides, nucleobases and dideoxynucleosides
suggesting it may also play a role in the cell membrane.11
The present lack of certainty regarding the exact localiza-
tion of hENT3 is not clariﬁed by the clinical features char-
acteristic of the H syndrome. Both mitochondrial and
lysosomal disorders are known for their extreme clinical
heterogeneity, for the involvement of multiple organs,an Journal of Human Genetics 83, 529–534, October 10, 2008 533
and for their progressive course.12,13 Many features of the
H syndrome are prevalent among patients with mitochon-
drial respiratory-chain defects, including the sensorineural
hearing loss, cardiomyopathy, hepatomegaly, endocrinop-
athy (especially the short stature, delayed puberty, and
early menopause), anemia, and hyperglycemia. Cutaneous
involvement is rare but has been described infrequently in
patients with mitochondrial disorders resulting from both
mitochondrial and nuclear-DNA mutations. These include
disorders of pigmentation (both hyper- and hypopigmen-
tation), hypertrichosis, erythematous eruptions, alopecia,
hair-shaft abnormalities, acrocyanosis, and multiple
lipomatosis.14,15 Lysosomal disorders13 are characterized
by mesenchymal and reticuloendothelial involvement,
which are also prominent in the H syndrome. However,
and most importantly, the lack of a storage material argues
against a lysosomal pathogenesis in this disorder. Further
characterization of the localization and function of normal
and mutated hENT3 is required.
The identiﬁcation of three different mutations, all in the
sixth exon of the gene, in ten affected families residing in
a small geographic region, and the resultant carrier rate of
1%, is striking. This relatively high carrier rate combined
with the marked phenotypic heterogeneity within our
families, some of which include mildly affected patients,
implies that H syndrome may be a largely underdiagnosed
condition. The occurrence of the same mutation (G427S)
in different populations indicates that the mutation might
reside in a hot spot in the SLC29A3 gene. We conclude that
sequence analysis of the SLC29A3 gene, or at least of its
sixth exon, is warranted in all patients presenting with
any unexplained combination of the above symptoms.
Supplemental Data
Two tables are available with this article online at http://www.
ajhg.org/.
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